

A comparison of the effect of pretreatment with intravenous dexamethasone, intravenous ketamine, and their combination, for suppression of remifentanil-induced cough: A randomized, double-blind, placebo-controlled clinical trial

Azim Honarmand, Mohammadreza Safavi, Farnaz Khalighinejad

Anesthesiology and Critical Care Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: The injection of remifentanil can cause cough during induction of anesthesia. This study was designed to examine the efficacy of ketamine, dexamethasone, and their combination on remifentanil-induced cough (RIC).

Materials and Methods: One hundred and twenty patients scheduled for elective surgery were randomly assigned into four groups: Group K received 10 mg ketamine; Group D received 10 mg dexamethasone; Group KD received 10 mg ketamine in combination with dexamethasone; and Group S received saline in a similar volume, five minutes prior to the injection of remifentanil. The incidence and severity of the cough was recorded in each person.

Results: The incidence of RIC was significantly lower in Group KD compared to Group K, Group D, and Group S (3.3 vs. 20%, 20%, and 46.7%, respectively, $P < 0.05$). The severity of RIC was significantly lower in Group KD compared to Group K, Group D, and Group S ($P < 0.05$). There was no significant difference between Group K and Group D in this regard ($P > 0.05$). There was no significant difference in the onset time of coughing among the four groups (19.8 ± 1.3 , 20.8 ± 0.9 , 19.0 ± 1.1 , and 19.9 ± 2.2 in Group K, Group D, Group KD, and Group S, respectively, $P > 0.05$).

Conclusion: We found that pretreatment with 10 mg ketamine in combination with 10 mg dexamethasone five minutes prior to the injection of remifentanil could significantly reduce the incidence of RIC, and it was better than using each drug singly.

Key Words: Cough, dexamethasone, ketamin, remifentanil

Address for correspondence:

Associate Prof. Mohammadreza Safavi, Anesthesiology and Critical Care Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.

E-mail: safavi@med.mui.ac.ir

Received: 17.07.2012, Accepted: 16.12.2012

Access this article online	
Quick Response Code:	Website: www.advbiores.net
	DOI: 10.4103/2277-9175.115808

INTRODUCTION

Remifentanil, a fentanyl derivative, is a specific mu-opioid receptor agonist with rapid onset and offset of action. Like other synthetic opioids, the injection of remifentanil can cause cough during induction of anesthesia. Studies have reported an incidence of about 25-34%.^[1,2]

Copyright: © 2013 Honarmand. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

How to cite this article: Honarmand A, Safavi M, Khalighinejad F. A comparison of the effect of pretreatment with intravenous dexamethasone, intravenous ketamine, and their combination, for suppression of remifentanil-induced cough: A randomized, double-blind, placebo-controlled clinical trial. Adv Biomed Res 2013;2:60.

Coughing during anesthetic induction is undesirable and has threatening complications for the patient, such as, increased cerebral, ocular or abdominal pressure and unstable hemodynamics. It is also associated with conjunctival and periorbital petechiae.^[3] Therefore, it is very important to prevent remifentanil-induced cough.

Many attempts have been made to date, to reduce the incidence of opioid-induced cough. For example, studies have shown that selective B-2 agonists terbutaline and salbutamol or beclomethasone can reduce fentanyl-induced cough.^[4,5] Intravenous lidocaine and low-dose ketamine and dexamethasone have suppressed both fentanyl and remifentanil-induced cough.^[1,2,6-9]

However, there are no studies on the effect of the combination of ketamine and dexamethasone on remifentanil-induced cough. Also there is no study that compares the efficacy of ketamine and dexamethasone on reducing remifentanil-induced cough. Hence, we have designed this randomized, double-blind, placebo-controlled clinical trial study, to evaluate and compare the efficacy of low-dose ketamine, dexamethasone, and their combination in reducing remifentanil-induced cough (RIC).

MATERIALS AND METHODS

After obtaining Institutional approval from the Ethics Committee of our university and taking written informed consent from the patients, the present study was performed on 120 ASA physical status I and II patients, of age 18 to 70 years, who were scheduled for elective surgery under general anesthesia.

The other inclusion criteria was patients with body weight less than 20% of the ideal body weight, with no history of smoking, chronic obstructive lung diseases, bronchial asthma, respiratory tract infection, or allergy to the study drugs. Also, patients treated with the angiotensin-converting enzyme inhibitor, bronchodilators, or steroids were excluded from the study. If there was any change in technique of anesthesia due to any problem, the patient was excluded from the study.

The patients were fasted for eight hours before operation. Prior to their arrival to the Operating Room, an 18 G cannula was inserted into the dorsal vein of the hand and a T-connector was connected to it for drug injection and infusion. No premedication was given to the patients.

After arrival to The Operating Room, patient monitoring was performed by an electrocardiogram (ECG),

noninvasive blood pressure measurement, and pulse oximetry throughout the study.

The patients were randomly divided into four groups by using computer-generated, random numbers: Group K: Five minutes prior to the injection of remifentanil, 10 mg of ketamine (Rotexmedica TRITTAU.GERMANY) in a volume of 3 ml was injected; Group D: Five minutes prior to the injection of remifentanil (Iran Daru), 10 mg of dexamethasone (Iran Hormone) in a volume of 3 ml was injected; Group KD: Five minutes prior to the injection of remifentanil, 10 mg ketamine in combination with 10 mg dexamethasone in a volume of 3 ml was injected; Group S: Five minutes prior to the injection of remifentanil, the same volume of saline was injected.

Remifentanil 1 µg/kg (diluted with normal saline to a concentration of 20 µg/ml) was administered at constant rate, over 10 seconds, by using an infusion pump. The preparation of study drugs and infusion of remifentanil was performed by an anesthesiologist who was not involved in data collection.

After starting remifentanil infusion, the onset time from the beginning of infusion of remifentanil to occurrence of cough and severity of cough were recorded for two minutes by a physician who was unaware of the study drug administered to the patients. The severity of coughing was recorded based on the number of episodes of cough as: Mild, 1-2; moderate, 3-4; severe, equal to or more than 5.

If arterial oxygen saturation (SpO₂) was less than 90% during remifentanil infusion, assisted ventilation with a mask was performed. If there was apnea, muscle rigidity or neuropsychological symptoms after remifentanil infusion, it was recorded. If breathing stopped for more than 15 seconds, it was considered as apnea. If the tone of the trunk muscle was increased where mask ventilation was difficult or impossible, it was considered as muscle rigidity. If patients developed a feeling of dissociation (such as body floating), drowsiness or numbness it was considered as a neuropsychological symptom.

Systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate (HR) and oxygen saturation of the patients were recorded immediately after arrival to the Operation Room (T₀), immediately after termination of remifentanil infusion (T₁), and after the injection of propofol (T₂). The time interval between T₀ and T₁ was 5-10 minutes, while the time interval between T₁ and T₂ was five minutes.

By using the statistical software, it was estimated that a minimal of 30 patients per group was needed to

obtain 80% statistical power, at the 95% significance level, for reducing 25% incidence of cough in comparison with the control group.

For analysis of data, we used the SPSS 16.0 (SPSS Inc, Chicago, IL, USA). The continuous variables such as age, weight, height, remifentanyl dosage, and onset time of cough were analyzed with one-way analysis of variance (ANOVA), with Bonferroni's correction. The categorical variables such as sex, ASA, incidence of cough, and frequency distribution of severity of cough were analyzed by the Chi-squared test. Repeated continuous variables such as SBP, DBP, and HR were analyzed by repeated measure analysis of variance. A P value less than 0.05 was considered statistically significant.

RESULT

In this study, a total of 129 consecutive patients were evaluated during one year with ASA I and II, who were candidates for elective surgery, under general anesthesia. Out of these, nine patients were excluded from the study. Subsequently, nine patients in four groups were unable to cooperate and were, therefore,

excluded from the study [Figure 1]. Therefore, 120 patients were included in the study and received study medication after randomization.

There was no significant difference in age, gender, weight, height, ASA class, or the total remifentanyl dose between the four groups [Table 1]. The SBP, DBP, HR the, and SpO2 changes at T0, T1, and T2 time intervals were not different between the four groups [Table 2].

Table 1: Patient demographic data and remifentanyl dose

	Group K (n = 30)	Group D (n = 30)	Group KD (n = 30)	Group S (n = 30)
Age (years)	34.2±14.5	35.1±12.1	34.9±15.2	35.3±15.5
ASA status (I/II)	29/1	25/5	27/3	26/4
Gender (M/F)	21/9	19/11	15/15	16/14
Weight (kg)	70.7±5.6	71.6±7.2	70.7±5.5	71.1±10.7
Height (cm)	1.69±0.1	1.68±0.05	1.68±0.1	1.67±0.2
Remifentanyl dose (µg)	78.1±7.5	77.1±6.3	76.2±2.3	77.9±5.6

Values are presented as mean±SD or number. Group K: Received 10 mg ketamine intravenously five minutes before injection of remifentanyl, Group D: Received 10 mg dexamethasone intravenously five minutes before injection of remifentanyl, Group KD: Received 10 mg ketamine intravenously combined with 10 mg dexamethasone intravenously five minutes before injection of remifentanyl, Group S: Received the same volume of saline five minutes before injection of remifentanyl. There was no significant difference between the four groups




Figure 1: Consort flow diagram

The incidence and severity of remifentanyl-induced cough (RIC) was significantly lower in Group KD when compared with Group K and Group D ($P < 0.05$) [Table 3]. These variables were also significantly less in Group K and Group D when compared with Group S ($P < 0.05$) [Table 3]. There was no significant difference between Group K and Group D in this regard ($P > 0.05$) [Table 3]. No significant difference was noted in the onset time of coughing among the four groups ($P > 0.05$) [Table 3]. No patient had apnea,

Table 2: Vital sign changes at different time intervals in the four groups

	Group K (n=30)	Group D (n=30)	Group KD (n=30)	Group S (n=30)
SBP (mmHg)				
T0	120.4±9.3	124.1±11.9	125.9±10.9	125.7±13.8
T1	115.2±7.7	116.1±9.1	116.6±5.0	115.8±12.5
T2	111.9±7.1	112.2±9.4	114.7±18.4	113.6±10.6
DBP (mmHg)				
T0	76.9±10.5	78.4±11.4	81.4±9.5	78.0±9.2
T1	70.6±7.5	71.9±9.1	73.9±6.8	72.9±10.1
T2	67.8±8.3	68.0±7.2	66.9±8.7	70.2±9.2
HR (bpm)				
T0	90.0±9.8	87.1±12.4	92.1±10.4	89.0±11.5
T1	78.8±6.6	82.8±11.0	84.3±9.4	83.4±16.7
T2	76.6±5.2	79.0±10.8	78.1±10.6	78.2±10.2
SpO2 (%)				
T0	98.2±1.3	97.2±1.3	98.1±1.5	97.9±1.4
T1	98.6±1.2	97.5±1.2	97.6±1.2	98.2±1.3
T2	98.2±1.1	98.3±1.1	98.2±1.3	98.1±1.2

Data are presented as mean±SD. Group K: Received 10 mg ketamine intravenously five minutes before injection of remifentanyl, Group D: Received 10 mg dexamethasone intravenously five minutes before injection of remifentanyl, Group KD: Received 10 mg ketamine intravenously combined with 10 mg dexamethasone intravenously five minutes before injection of remifentanyl, Group S: Received the same volume of saline five minutes before injection of remifentanyl, SBP: Systolic blood pressure, DBP: Diastolic blood pressure, HR: Heart rate, SpO2: Arterial oxygen saturation, T0: Immediately after arriving at Operation Room, T1: Immediately after injection of remifentanyl, T2: Immediately after injection of propofol. No statistical difference was observed among the four groups

Table 3: The incidence, onset time, and severity of coughing after remifentanyl infusion

	Group K (n=30)	Group D (n=30)	Group KD (n=30)	Group S (n=30)
Incidence of cough (%)	6 (20)*	6 (20)*	1 (3.3)*†	17 (46.7)
Onset of coughing	19.8±1.3	20.8±0.9	19.0±1.1	19.9±2.2
Severity of cough				
Mild	4 (66.6)*	5 (83.3)*	1 (100)*†	8 (47)
Moderate	2 (33.3)*	1 (16.6)*	0 (0)*†	8 (47)
Severe	0 (0)*	0 (0)*	0 (0)*	1 (5.8)

The data are presented as mean±SD or numbers (%). Group K: Received 10 mg ketamine intravenously five minutes before injection of remifentanyl, Group D: Received 10 mg dexamethasone intravenously five minutes before injection of remifentanyl, Group KD: Received 10 mg ketamine intravenously combined with 10 mg dexamethasone intravenously five minutes before injection of remifentanyl, Group S: Received the same volume of saline five minutes before injection of remifentanyl. Severity of cough: Mild (1-2), moderate (3-5), severe (6-5), * $P < 0.05$ compared with Group S, † $P < 0.05$ compared with Group K and Group D. There was no significant difference between Group K and Group D

stiffness, arrhythmias, or oxygen desaturation in any group.

DISCUSSION

Our study showed that pretreatment with 10 mg ketamine in combination with dexamethasone 10 mg intravenously, five minutes prior to the infusion of remifentanyl, could significantly reduce the incidence of remifentanyl-induced cough from 46.7% in Group S to 3.3% in Group KD. In addition, the severity of cough in Group KD was significantly less in comparison to Group S.

Our data showed that using ketamine 10 mg or dexamethasone 10 mg intravenously, five minutes before remifentanyl infusion, significantly reduced the incidence and severity of remifentanyl-induced cough. No significant difference was noted between Group K and Group D with respect to this variable.

Several reports have been recently published using different drugs to prevent the opioid-induced cough.^[1,2,4-6,9,10-13] Although several mechanisms responsible for opioid-induced cough have been explained, its exact mechanism is not yet known. Some studies have reported that opioids may block the central sympathetic nervous system, thus activating the parasympathetic nervous system, which can provoke cough and reflex bronchoconstriction.^[4,5,8,10]

Another likely mechanism includes stimulation of the pulmonary chemoreflex, which is mediated by rapidly adapting irritant receptors or vagal C-fiber receptors that are in proximity to the pulmonary vessels (juxtacapillary receptors).^[11,12]

Furthermore, opioid receptors have been identified in the trachea, bronchi, and alveolar walls. Another possible mechanism is that opioids constrict the bronchial smooth muscle and this causes remodeling of the bronchial wall. This stimulates the receptors, which trigger the cough reflex.^[13,14]

The presence of N-methyl-D-aspartate (NMDA) receptors has been shown in the larynx, lung, and airways, and activation of these receptors can trigger airway constriction.^[15-17] Ketamine is a noncompetitive NMDA receptor antagonist. Therefore, the direct or indirect effect of ketamine on the airway smooth muscle may be attributed to its NMDA receptor antagonism effect.^[16,18,19]

Ketamine inhibits Ca^{2+} influx and consequently decreases the bronchomotor tone.^[19] As Durieux et al.^[20] shows, ketamine suppresses the muscarinic signaling that finally causes bronchodilation.

It has been reported that dexamethasone increases the activation of neutral endopeptidase, which reverses the enhanced airway reactivity of the airway epithelial cells.^[21-23] It has been reported that corticosteroids increase the beta adrenergic receptors in the pulmonary cells.^[24] Also it has been used as a mast cell stabilizer. Murlas *et al.*^[25] have reported that in guinea pigs dexamethasone improves bronchoconstriction mediated by tachykinin, which induces contraction of the smooth muscle. It has been shown that tachykinin induces the release of histamine from the mast cell in the airway, which facilitates the excitation of the receptors. Dexamethasone inhibits the release of tachykinin and consequently the excitation of the receptors.^[21,26]

Kim *et al.*^[2] reported that administration of 0.1 mg/kg ketamine, one minute before injection of remifentanil, was effective in reducing remifentanil-induced cough. The incidence of RIC in their study was 27.6%, while in our study it was 46.7%. This difference in incidence of RIC was due to the difference in dose and timing of the remifentanil administered. The dosage of remifentanil used in our study was not based on target controlled infusion (TCI). This could be another cause of the difference between our results and those of the Kim *et al.* study.

Yu *et al.*^[7] reported that administration of 10 mg of dexamethasone prior to the injection of remifentanil reduced the incidence and severity of remifentanil induced cough. Their results were similar to the findings in the Kim *et al.* study.^[1]

The results of our study were in agreement with the Kim *et al.* and Yu *et al.* studies. We showed that administration of ketamine in combination with dexamethasone was significantly more effective than using each drug singly, for reducing the incidence and severity of remifentanil-induced cough. This could probably be attributed to the synergistic effect of ketamine with dexamethasone, and must be documented in future studies.

One limitation of our study was administration of 10 mg ketamine or 10 mg dexamethasone singly or in combination, regardless of the patients' body weight. We recommend conducting more studies with the exact dose of each drug, based on the patients' weight.

In conclusion, our study showed that the combined use of ketamine 10 mg with dexamethasone 10 mg reduced the incidence and severity of remifentanil-induced cough, without developing significant adverse effects, and it was better than using each drug singly. In addition, we found that there was no significant difference between using ketamine or dexamethasone

for controlling the cough following remifentanil infusion.

ACKNOWLEDGMENT

The authors wish to sincerely thank the support of all their colleagues in the Kashani Hospital Medical Center, affiliated to the Isfahan University of Medical Sciences, in Isfahan, Iran. Furthermore, their special thanks go to the patients, who wholeheartedly and actively assisted them in carrying out this research. No conflict of interest exists. This prospective randomized observational study was approved by the Ethics Committee of their university, (Isfahan University of Medical Sciences) and all the patients gave a written, informed consent. This article is extracted from the approved project No. 391239. IRCT NUMBER IS 201210255362N4(www.irct.ir).

REFERENCES

- Kim JY, Lee SY, Kim DH, Park SK, Min SK. Effect-site concentration of propofol for reduction of remifentanil-induced cough. *Anaesthesia* 2010;65:697-703.
- Cho HB, Kwak HJ, Park SY, Kim JY. Comparison of the incidence and severity of cough after alfentanil and remifentanil injection. *Acta Anaesthesiol Scand* 2010;54:717-20.
- Tweed WA, Dakin D. Explosive coughing after bolus fentanyl injection. *Anesth Analg* 2001;92:1442-3.
- Lui PW, Hsing CH, Chu YC. Terbutaline inhalation suppresses fentanyl-induced coughing. *Can J Anaesth* 1996;43:1216-9.
- Agarwal A, Azim A, Ambesh S, Bose N, Dhiraj S, Sahu D, *et al.* Salbutamol, beclomethasone or sodium chromoglycate suppress coughing induced by iv fentanyl. *Can J Anaesth* 2003;50:297-300.
- Lin CS, Sun WZ, Chan WH, Lin CJ, Yeh HM, Mok MS. Intravenous lidocaine and ephedrine, but not propofol, suppress fentanyl induced cough. *Can J Anaesth* 2004;51:654-9.
- Yu MS, Kim JY, Kim HY. Intravenous dexamethasone pretreatment reduces remifentanil-induced cough. *Korean J Anesthesiol* 2011;60:403-7.
- Pandey CK, Raza M, Ranjan R, Lakra A, Agarwal A, Singh U, *et al.* Intravenous lidocaine suppresses fentanyl-induced coughing: A double-blind, prospective, randomized placebo-controlled study. *Anesth Analg* 2004;99:1696-8.
- Yeh CC, Wu CT, Huh BK, Lee MS, Lin SL, Sheen MJ, *et al.* Premedication with intravenous low-dose ketamine suppresses fentanyl-induced cough. *J Clin Anesth* 2007;19:53-6.
- Reitan JA, Stengert KB, Wymore ML, Martucci RW. Central vagal control of fentanyl-induced bradycardia during halothane anesthesia. *Anesth Analg* 1978;57:31-6.
- Paintal AS. Mechanism of stimulation of type J pulmonary receptors. *J Physiol* 1969;203:11-32.
- Bohrer H, Fleischer F, Werning P. Tussive effect of a fentanyl bolus administered through a central venous catheter. *Anaesthesia* 1990;45:18-21.
- Horng HC, Wong CS, Hsiao KN, Huh BK, Kuo CP, Cherng CH, *et al.* Pre-medication with intravenous clonidine suppresses fentanyl-induced cough. *Acta Anaesthesiol Scand* 2007;51:862-5.
- Yasuda I, Hirano T, Yusa T, Satoh M. Tracheal constriction by morphine and by fentanyl in man. *Anesthesiology* 1978;49:117-9.
- Said SI, Berisha HI, Pakbaz H. N-Methyl-d-aspartate receptors outside the central nervous system: Activation causes acute lung injury that is mediated by nitric oxide synthesis and prevented by vasoactive intestinal peptide. *Neuroscience* 1995;65:943-6.
- Sato T, Hirota K, Matsuki A, Zsigmond EK, Rabito SF. The role of the N-methyl-d-aspartate receptor in the relaxant effect of ketamine on tracheal smooth muscle. *Anesth Analg* 1998;87:1383-8.
- Robertson BS, Satterfield BE, Said SI, Dey RD. N-Methyl-d-aspartate

- receptors are expressed by intrinsic neurons of rat larynx and esophagus. *Neurosci Lett* 1998;244:77-80.
18. Cheng EY, Mazzeo AJ, Bosnjak ZJ, Coon RL, Kampine JP. Direct relaxant effects of intravenous anesthetics on airway smooth muscle. *Anesth Analg* 1996;83:162-8.
 19. Kamei J, Tanihara H, Igarashi H, Kasuya Y. Effects of N-methyl-daspartate antagonists on the cough. *Eur J Pharmacol* 1989;168:153-8.
 20. Durieux ME. Inhibition by ketamine of muscarinic acetylcholine receptor function. *Anesth Analg* 1995;81:57-62.
 21. Krumins SA, Broomfield CA. Evidence of NK1 and NK2 tachykinin receptors and their involvement in histamine release in a murine mast cell line. *Neuropeptides* 1992;21:65-72.
 22. Murlas CG, Lang Z, Williams GJ, Chodimella V. Aerosolized neutral endopeptidase reverses ozone-induced airway hyperreactivity to substance P. *J Appl Physiol* 1992;72:1133-41.
 23. Lang Z, Murlas CG. Neutral endopeptidase of a human airway epithelial cell line recovers after hypochlorous acid exposure: Dexamethasone accelerates this by stimulating neutral endopeptidase RNA synthesis. *Am J Respir Cell Mol Biol* 1992;7:300-6.
 24. Fraser CM, Venter JC. The synthesis of beta-adrenergic receptors in cultured human lung cells: Induction by glucocorticoids. *Biochem Biophys Res Commun* 1980;94:390-7.
 25. Murlas CG, Lang Z, Chodimella V. Dexamethasone reduces tachykinin but not ACh airway hyperreactivity after O₃. *Lung* 1993;171:109-21.
 26. Tournoy KG, De Swert KO, Leclere PG, Lefebvre RA, Pauwels RA, Joos GF. Modulatory role of tachykinin NK1 receptor in cholinergic contraction of mouse trachea. *Eur Respir J* 2003;21:3-10.

Source of Support: Anesthesiology and Critical Care Research Center, Isfahan University of Medical Sciences, Isfahan, Iran. **Conflict of Interest:** None declared.